# Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial

> **NCT06063057** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 744 (estimated)

## Conditions studied

- Hand, Foot and Mouth Disease
- Herpangina

## Interventions

- **BIOLOGICAL:** low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
- **BIOLOGICAL:** medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
- **BIOLOGICAL:** high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
- **BIOLOGICAL:** Enterovirus type EV71 vaccine (Vero cell), Inactivated

## Key facts

- **NCT ID:** NCT06063057
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-20
- **Primary completion:** 2025-12-19
- **Final completion:** 2026-03-10
- **Target enrollment:** 744 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063057, "Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06063057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*